Michael Hier
Papers
6
Total Citations
487
H-Index
4
About
Michael Hier is a head and neck oncology researcher whose work has fundamentally shaped the clinical debate around treatment selection for oropharyngeal squamous cell carcinoma (OPSCC), particularly in the context of the rising HPV-associated epidemic. He is best known as a key contributor to the landmark ORATOR trial, a phase 2 randomized study comparing radiotherapy against transoral robotic surgery (TORS) with neck dissection for oropharyngeal cancer, which has accumulated an impressive 458 citations since its 2019 publication and remains a cornerstone reference in the field. His research consistently interrogates how treatment modality affects patient quality of life, driving important conversations around de-escalation strategies for HPV-positive patients who often carry an excellent prognosis. Through both clinical trials and exploratory studies examining neoadjuvant chemotherapy combined with TORS, Hier has worked to identify pathways that preserve oncologic outcomes while reducing treatment-related toxicity. His historical and conceptual contributions — tracing how HPV discovery catalyzed the adoption of robotic surgical approaches — further demonstrate his breadth of scholarly engagement. Together, his body of work positions him as a meaningful voice in the evolving, multidisciplinary management of head and neck cancer.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4
- 5
- 6